

R. Bordet is doctor of medicine, neurologist and clinical pharmacologist. He obtained a PhD in experimental pharmacology in 1999. He is Professor of medical pharmacology University of Lille and hospital practitioner at the Lille University Hospital. The topic of his translational research is focused on experimental and clinical neuropsychopharmacology in the field of neurological diseases and of mental diseases, with emphasis on development of both symptomatic and disease-modifying pharmacological approaches on cognition and behavior. R Bordet is the head of U1171 (Lille University, Inserm, Lille University Hospital), a research unit dedicated to 'Degenerative & vascular cognitive disorders' with an emphasis on post-stroke cognitive disorders and its interaction with Alzheimer's disease. He is the academic coordinator of the Pharmacog consortium supported by IMI project to develop new biomarkers for drug development in Alzheimer's disease. He has an international visibility on the place of nuclear receptors, in particular PPAR that modulates both lipid and glucose metabolism, as disease-modifier in different brain diseases. He is PI of several cohort studies and of clinical trials. He developed an experimental and clinical platform to explore cognition in animal, healthy volunteers and patients. He has published 220 articles.